Q3 2024 Bayer AG Earnings Call Transcript

Nov 12, 2024 / 01:00 PM GMT

Release Date Price: €20.88 (-14.50%)

Transcript

Key Points

Positve

Bayer AG (BAYRY) is on track to meet its full-year targets for sales growth, core earnings per share, and free cash flow.
The Pharmaceuticals division is performing well, with Nubeqa reaching blockbuster status and strong growth in other launch products.
Consumer Health division achieved a 6% year-over-year sales growth in the third quarter, driven by strong performance in cough and cold products.
The company is making significant progress in its strategic agenda, including innovation in its Pharma pipeline and operational efficiency improvements.
Bayer AG (BAYRY) has successfully scaled its new operating model, resulting in a leaner organization with improved decision-making processes.

Negative

The Crop Science division is facing challenges, with sales expected to decline due to weather issues, commodity price softness, and generic pricing pressure.
Regulatory challenges, particularly in the Crop Science division, could have a material impact on top and bottom lines in 2025.
Foreign exchange headwinds have significantly impacted financial performance, with a EUR440 million hit to the top line in Q3.
Litigation, particularly related to Glyphosate, remains a significant issue with ongoing trials and potential Supreme Court involvement.
The company anticipates a muted outlook for 2025, with likely declining earnings due to rising generic headwinds and regulatory challenges.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BAYGn.DE - Bayer AG
Q3 2024 Bayer AG Earnings Call
Nov 12, 2024 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and good morning, everybody and welcome to our conference call for the third quarter of 2024.

Bill will kick off our presentation today by sharing his perspective on business development, year-to-date and the progress we've made towards our strategic objectives.

Following this, Wolfgang will provide a summary of our financial performance in the third quarter, discuss the full year outlook for this year and outline key trends for 2025.

Today, we have also invited our divisional heads to present detailed insights into the growth dynamics and future outlook of their respective businesses. And as usual, the presentations will then be followed by a Q&A session before we begin. I'd like to highlight the cautionary

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.